ABSCI CORP (ABSI) Stock News
NASDAQ:ABSI - Nasdaq - US00091E1091 - Common Stock - Currency: USD
ABSI Latest News and Analysis
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses deep learning AI and synthetic biology to expand proteins’ therapeutic potential. The rapid growth of artificial intelligence/machine learning (AI/ML) has led to the emergence of numerous companies that are difficult to tell apart. This challenge is worsened by the fact that clinical proof of concept (POC) in this area is still years away. Recently, Absci entered into a s
Gapping stocks in Wednesday's session
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.
Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference
VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company,...
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery...
Absci Stock Jumps As AMD Invests $20M To Boost AI Drug Discovery
AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the company entered into a strategic collaboration with Advanced Micro Devices Inc (NASDAQ:AMD) to enhance its AI drug discovery capabilities. The partnership will leverage AMD Instinct accelerators and ROCm software to support Absci’s advanced de novo antibody design models. The deal also includes a $20 million private investment in public equity (PIPE) by AMD, underscoring the ris
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct...
Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health
Collaboration leverages Absci’s leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications
Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health
Collaboration leverages Absci’s leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health...
Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
VANCOUVER, Wash. and NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company,...
Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day
Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day
Drug candidate selected for ABS-201, a novel, potentially category-defining anti-PRLR antibody in development for androgenic alopecia Leading AI...
Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference
Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration Entered into collaboration...
Absci to Host R&D Day on December 12, 2024
Absci to Host R&D Day on December 12, 2024
VANCOUVER, Wash. and NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company,...
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
Collaboration brings together Absci’s Generative AI drug creation platform with Twist’s DNA synthesis platform to accelerate the design of a novel therapeutic antibody